Valuation: Gennex Laboratories Limited

Market Cap 212.58Cr 2.24Cr 2Cr 1.84Cr 1.67Cr 3.14Cr 3.22Cr 22Cr 8.84Cr 112.2Cr 8.42Cr 8.24Cr 355.62Cr P/E 2025
15.4x
P/E 2026 8.26x
Enterprise Value 254.53Cr 2.69Cr 2.4Cr 2.21Cr 2Cr 3.76Cr 3.86Cr 26Cr 11Cr 134.34Cr 10Cr 9.87Cr 425.8Cr EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
66.61%
Yield 2025 *
-
Yield 2026 -
01/10 Gennex Laboratories Limited Announces Board Changes CI
14/08 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
30/05 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
14/02 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
14/02 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
14/02 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
14/11 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/25/14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/25/30 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/25/30 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/25/30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/25/14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/25/14 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
1 day+6.58%
1 week-1.46%
Current month+9.10%
1 month-10.71%
3 months-3.31%
6 months-12.41%
Current year-38.81%
1 week 7.7
Extreme 7.7
9.2
1 month 7.7
Extreme 7.7
10.25
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
16.3
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 18/05/2012
Director of Finance/CFO - 12/11/2024
Compliance Officer 62 20/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 21/12/2020
Director/Board Member 62 01/10/2024
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%-1.46%-43.40%-22.29% 2.11Cr
-0.11%+9.94%+57.20%+148.21% 1,25700Cr
-1.62%-0.95%+42.90%+75.88% 65TCr
-0.98%-0.14%+34.93%+102.23% 51TCr
-1.56%-1.39%+51.02%+64.18% 39TCr
-2.49%+2.01%+75.38%+39.94% 37TCr
-0.02%+3.15%+32.47%+55.33% 30TCr
-0.72%+7.32%+11.29%+33.98% 29TCr
-0.90%+2.97%+55.67%+70.93% 25TCr
-1.68%+5.27%+37.21%+105.26% 21TCr
Average -0.35%+2.53%+35.47%+67.36% 42.27TCr
Weighted average by Cap. -0.95%+4.15%+47.32%+93.23%

Financials

2025 2026
Net sales 137.9Cr 1.46Cr 1.3Cr 1.19Cr 1.09Cr 2.04Cr 2.09Cr 14Cr 5.74Cr 73Cr 5.46Cr 5.35Cr 230.7Cr 172.74Cr 1.82Cr 1.63Cr 1.5Cr 1.36Cr 2.55Cr 2.62Cr 18Cr 7.19Cr 91Cr 6.84Cr 6.7Cr 288.98Cr
Net income 18Cr 19.13L 17.09L 15.7L 14.26L 26.78L 27.45L 1.87Cr 75.39L 9.57Cr 71.81L 70.27L 30Cr 21Cr 22.15L 19.79L 18.17L 16.51L 31L 31.78L 2.17Cr 87.27L 11Cr 83.13L 81.35L 35Cr
Net Debt -27Cr -29.01L -25.91L -23.8L -21.62L -40.6L -41.62L -2.84Cr -1.14Cr -15Cr -1.09Cr -1.07Cr -46Cr 42Cr 44.28L 39.56L 36.34L 33.01L 61.98L 63.54L 4.34Cr 1.75Cr 22Cr 1.66Cr 1.63Cr 70Cr
Projected Income Statement - Annual - Gennex Laboratories Limited
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
125
Date Price Change Volume
03/26/03 ₹8.750 +6.58% 3,21,525
02/26/02 ₹8.210 +2.37% 10,53,207
30/26/30 ₹8.020 -10.49% 13,21,688
29/26/29 ₹8.960 -1.54% 1,88,622
28/26/28 ₹9.100 +2.48% 2,86,354
  1. Stock Market
  2. Stocks
  3. 531739 Stock